Global Acute Respiratory Distress Syndrome Treatment Market 2024-2028

Description

List of Tables

The acute respiratory distress syndrome treatment market is forecasted to grow by USD 1.22 bn during 2023-2028, accelerating at a CAGR of 6.9% during the forecast period. The report on the acute respiratory distress syndrome treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing focus on lung-protective ventilation strategies, advances in precision medicine and biomarker research, and increasing utilization of ecmo therapy.

Technavio's acute respiratory distress syndrome treatment market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.2%
CAGR	6.9%
Incremental Value	$1.22bn

By Distribution Channel

Hospitals pharmacies
Retail pharmacies
Online pharmacies

By Route Of Administration

Oral
Injection
Inhalation

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the growing interest in immunomodulatory therapies for ards as one of the prime reasons driving the acute respiratory distress syndrome treatment market growth during the next few years. Also, emergence of ards drug repurposing strategies and increasing recognition of multimodal supportive care for ards will lead to sizable demand in the market.

The report on the acute respiratory distress syndrome treatment market covers the following areas:

Acute respiratory distress syndrome treatment market sizing
Acute respiratory distress syndrome treatment market forecast
Acute respiratory distress syndrome treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading acute respiratory distress syndrome treatment market vendors that include Air Liquide SA, Athersys Inc., Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., and APEPTICO Forschung und Entwicklung GmbH. Also, the acute respiratory distress syndrome treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR77729

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

4.1 Global acute respiratory distress syndrome treatment market 2018 - 2022
4.2 Distribution Channel Segment Analysis 2018 - 2022
4.3 Route of Administration Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition

6 Market Segmentation by Distribution Channel

6.1 Market segments
6.2 Comparison by Distribution Channel
6.3 Hospitals pharmacies - Market size and forecast 2023-2028
6.4 Retail pharmacies - Market size and forecast 2023-2028
6.5 Online pharmacies - Market size and forecast 2023-2028
6.6 Market opportunity by Distribution Channel

7 Market Segmentation by Route of Administration

7.1 Market segments
7.2 Comparison by Route of Administration
7.3 Oral - Market size and forecast 2023-2028
7.4 Injection - Market size and forecast 2023-2028
7.5 Inhalation - Market size and forecast 2023-2028
7.6 Market opportunity by Route of Administration

8 Customer Landscape

8.1 Customer landscape overview

9 Geographic Landscape

9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 China - Market size and forecast 2023-2028
9.9 Germany - Market size and forecast 2023-2028
9.10 UK - Market size and forecast 2023-2028
9.11 France - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

12.1 Vendors covered
12.2 Market positioning of vendors
12.3 APEPTICO Forschung und Entwicklung GmbH
12.4 Athersys Inc.
12.5 Dragerwerk AG and Co. KGaA
12.6 Edesa Biotech Inc.
12.7 Fisher and Paykel Healthcare Corp. Ltd.
12.8 GE Healthcare Technologies Inc.
12.9 Getinge AB
12.10 Hamilton Medical AG
12.11 Koninklijke Philips N.V.
12.12 LivaNova PLC
12.13 Medtronic
12.14 Nihon Kohden Corp.
12.15 ResMed Inc.
12.16 Smiths Group Plc
12.17 Vyaire Medical Inc.

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations